Goshua, G., Pine, A.B., Meizlish, M.L., Chang, C.-H., Zhang, H., Bahel, P., Baluha, A., Bar, N., Bona, R.D., Burns, A.J., et al. (2020) Endotheliopathy in COVID-19- Associated Coagulopathy: Evidence from a Single-Centre, Cross-Sectional Study. The Lancet Haematology, 7, e575-e582.
https://doi.org/10.1016/S2352-3026(20)30216-7

has been cited by the following article:

• TITLE: SARS-COV-2 Induce Pulmonary Injury from Basic to Clinical Research

  AUTHORS: Jinguo Zhu

  KEYWORDS: COVID-19, SARS-CoV-2, Pulmonary Injury, Clinical Manifestation, Treatment Strategies

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.12 No.3, March 31, 2022

  ABSTRACT: The SARS-CoV-2 has infected over 194,909,000 cases and over 4,170,000 deaths in the world before the end of July 2021. The virus attacks human alveoli and induces severe lung injury (COVID-19 disease) and spreads rapidly. The mechanisms of COVID-19 disease are unclear. To better understand this disease, This review analyzes the SARS-CoV-2 biological characteristics, insights the effect of alveolar epithelium and its adjacent microvascular endothelium, investigates human host cells immune response and immunothrombosis. Explains clinical manifestations of COVID-19 associated lung injury. It may be helpful for development management strategies for COVID-19 associated pulmonary damage.